A First-in-human phase I study of RO7122290 given as a single agent and in combination with atezolizumab to patients with advanced solid tumours
Latest Information Update: 09 Oct 2020
At a glance
- Drugs Atezolizumab (Primary) ; RG 7827 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 09 Oct 2020 New trial record
- 21 Sep 2020 Preliminary results of Part A (n=62) and Part B (n=39) in patients treated with RO 7122290 weekly at escalated dose levels presented at the 45th European Society for Medical Oncology Congress